Axsome Therapeutics (AXSM) Competitors $103.02 +1.64 (+1.62%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$104.02 +1.01 (+0.98%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AXSM vs. JAZZ, INSM, TEVA, GMAB, MRNA, RDY, QGEN, VTRS, ASND, and VRNAShould you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Jazz Pharmaceuticals (JAZZ), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "medical" sector. Axsome Therapeutics vs. Its Competitors Jazz Pharmaceuticals Insmed Teva Pharmaceutical Industries Genmab A/S Moderna Dr. Reddy's Laboratories Qiagen Viatris Ascendis Pharma A/S Verona Pharma PLC American Depositary Share Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations. Does the media refer more to AXSM or JAZZ? In the previous week, Axsome Therapeutics and Axsome Therapeutics both had 7 articles in the media. Axsome Therapeutics' average media sentiment score of 1.22 beat Jazz Pharmaceuticals' score of 1.12 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AXSM or JAZZ more profitable? Jazz Pharmaceuticals has a net margin of 11.86% compared to Axsome Therapeutics' net margin of -64.39%. Jazz Pharmaceuticals' return on equity of 26.62% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Axsome Therapeutics-64.39% -272.80% -36.69% Jazz Pharmaceuticals 11.86%26.62%9.14% Which has preferable valuation and earnings, AXSM or JAZZ? Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxsome Therapeutics$385.69M13.15-$287.22M-$5.77-17.85Jazz Pharmaceuticals$4.06B1.72$560.12M$7.5015.40 Do analysts recommend AXSM or JAZZ? Axsome Therapeutics currently has a consensus target price of $172.33, indicating a potential upside of 67.28%. Jazz Pharmaceuticals has a consensus target price of $181.64, indicating a potential upside of 57.24%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 3.06Jazz Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Do institutionals & insiders believe in AXSM or JAZZ? 81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 22.3% of Axsome Therapeutics shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, AXSM or JAZZ? Axsome Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. SummaryAxsome Therapeutics and Jazz Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXSM vs. The Competition Export to ExcelMetricAxsome TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.99B$3.00B$5.47B$9.53BDividend YieldN/A2.44%4.74%4.08%P/E Ratio-17.8517.6228.6723.80Price / Sales13.15269.12422.3188.12Price / CashN/A41.9535.4557.96Price / Book87.318.508.275.55Net Income-$287.22M-$55.06M$3.24B$259.03M7 Day Performance2.17%-3.98%-3.63%-4.56%1 Month Performance-0.86%9.59%4.40%4.49%1 Year Performance22.03%6.72%25.97%18.05% Axsome Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXSMAxsome Therapeutics4.8236 of 5 stars$103.02+1.6%$172.33+67.3%+19.8%$4.99B$385.69M-17.85380Positive NewsUpcoming EarningsJAZZJazz Pharmaceuticals4.8563 of 5 stars$117.38-0.7%$181.64+54.7%+1.0%$7.10B$4.07B15.652,800Positive NewsUpcoming EarningsINSMInsmed3.768 of 5 stars$101.75-2.1%$109.20+7.3%+44.3%$19.30B$363.71M-17.101,271Upcoming EarningsTEVATeva Pharmaceutical Industries3.963 of 5 stars$16.53-0.1%$24.71+49.5%-12.3%$18.96B$16.62B-14.3736,830News CoveragePositive NewsEarnings ReportGMABGenmab A/S3.5405 of 5 stars$23.09-1.3%$37.80+63.7%-23.2%$14.81B$3.12B13.122,682News CoverageUpcoming EarningsShort Interest ↑MRNAModerna4.4648 of 5 stars$33.91-0.7%$46.11+36.0%-70.7%$13.11B$3.24B-3.885,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownRDYDr. Reddy's Laboratories1.9595 of 5 stars$14.71+0.2%$16.95+15.3%-15.5%$12.28B$3.81B22.2827,811QGENQiagen3.3039 of 5 stars$51.00-1.5%$49.40-3.1%+12.1%$11.34B$1.98B127.875,765Upcoming EarningsVTRSViatris2.2106 of 5 stars$9.26-1.6%$10.40+12.3%-26.3%$10.87B$14.74B-2.9232,000Upcoming EarningsShort Interest ↑ASNDAscendis Pharma A/S3.0633 of 5 stars$164.16-2.0%$223.07+35.9%+27.8%$10.04B$368.70M-26.141,017Analyst ForecastVRNAVerona Pharma PLC American Depositary Share2.1781 of 5 stars$105.09-0.2%$109.00+3.7%+365.2%$8.95B$42.28M-52.5530Positive NewsUpcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies JAZZ Alternatives INSM Alternatives TEVA Alternatives GMAB Alternatives MRNA Alternatives RDY Alternatives QGEN Alternatives VTRS Alternatives ASND Alternatives VRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AXSM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
